NEU 0.00% $19.97 neuren pharmaceuticals limited

perseis - value of licensing

  1. 13,916 Posts.
    lightbulb Created with Sketch. 124
    Interesting paper concerning valuation of antibody licensing deals.

    Says the majority of pre-clinical deals attracted below $10M, depending on a whole range of factors such as the pharma involved, milestone payments, number of candidates, and royalty arrangement.

    It would be good to see Perseis arrange a deal prior to NNZ outcome to provide some kind of safety net should NNZ flop.

    While the money may not be uber great, a bluechip Big Pharma signing up for our antibodies would provide validation of a pipeline product and put us on the radar.


    http://www.venturevaluation.com/vv_web/files/BIO_2011_deal_making_antibody.pdf
 
watchlist Created with Sketch. Add NEU (ASX) to my watchlist
(20min delay)
Last
$19.97
Change
0.000(0.00%)
Mkt cap ! $2.552B
Open High Low Value Volume
$19.96 $19.97 $19.69 $4.156M 209.6K

Buyers (Bids)

No. Vol. Price($)
1 246 $19.88
 

Sellers (Offers)

Price($) Vol. No.
$19.99 512 1
View Market Depth
Last trade - 16.10pm 05/07/2024 (20 minute delay) ?
NEU (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.